Wieslab Laboratory Services are proud to be one of the first diagnostic laboratories in Scandinavia to offer neurofilament light (NfL) testing in serum.
With the newest addition to our technology platform, we are able to use a single molecule array digital ELISA (SIMOA) to evaluate neurofilament light chain (NfL) in serum.
NfL is a well-known biomarker for measuring disease activity, treatment response and prognosis in patients with neurodegenerative disorders.
Being able to test NfL levels in serum facilitates patient care.
Wieslab Laboratory Services are proud to be one of the first diagnostic laboratories in Scandinavia to offer neurofilament light (NfL) testing in serum.
With the newest addition to our technology platform, we are able to use a single molecule array digital ELISA (SIMOA) to evaluate neurofilament light chain (NfL) in serum.
NfL is a well-known biomarker for measuring disease activity, treatment response and prognosis in patients with neurodegenerative disorders.
Being able to test NfL levels in serum facilitates patient care.
ENGLISH
During the first weeks of the year, we have installed, validated and quality assured a new analytical instrument from Quanterix - a single molecule array (SIMOA©) - a digital ultrasensitive ELISA - to offer e.g. test of Neurofilament light (NfL) in serum.
Measurement of NfL levels is of interest in disease activity, treatment response and prognosis in patients with neurodegenerative diseases. Being able to offer NfL tests in serum and / or CSF provides a good choice for both doctor and patient.
We start receiving sample material on April 1, 2020.
SVENSKA
Under årets första veckor har vi installerat, validerat och kvalitetssäkrat ett nytt analysinstrument från Quanterix - a single molecule array (SIMOA©) - en digital ultrasensitiv ELISA - för att kunna erbjuda ex. test av Neurofilament light (NfL) i serum.
Mätning av NfL nivåer är av intresse för sjukdomsaktivitet, behandlingsrespons och prognos hos patienter med neurodegenerativa sjukdomar. Att kunna erbjuda NfL test i serum och/eller likvor ger en bra valmöjlighet för både doktor och patient.
Vi börjar att ta emot provmaterial den 1:a april, 2020.